BRL Medicine Inc.
BRL Medicine is a privately held Shanghai company developing gene and cell therapies. Its lead candidate BRL-101 is in a pivotal Phase 2 study in China, and BRL-303 received IND clearance for systemic sclerosis in October 2026.
| Headquarters | Shanghai, China |
|---|---|
| Listing | Private |
| Lead asset / stage | BRL-101 Pivotal Phase 2 — China |
| Latest event | BRL-303 received China IND clearance for systemic sclerosis and was included in the CDE care programme. |